Who faces higher risk from tigecycline liver damage?
Tigecycline, an antibiotic for complicated infections, carries a boxed warning for increased mortality risk but also hepatotoxicity, including elevated liver enzymes and rare acute liver injury. Adults with pre-existing liver disease or conditions impairing hepatic function are at higher risk, as tigecycline relies heavily on liver metabolism and biliary excretion.[1][2]
How does liver impairment affect tigecycline dosing?
No dose adjustment is needed for mild to moderate liver impairment (Child-Pugh A or B). For severe impairment (Child-Pugh C), start with a 100 mg loading dose, then reduce to 25 mg every 12 hours. This minimizes accumulation, but monitoring ALT, AST, and bilirubin remains essential, especially in cirrhosis patients.[1][3]
What patient factors raise tigecycline hepatotoxicity odds?
- Obesity and high BMI: Higher exposure due to larger volume of distribution; case reports link it to severe liver injury in obese adults.[4]
- Elderly patients: Age-related liver function decline increases susceptibility, with post-marketing data showing more frequent enzyme elevations.[2]
- Alcohol use or fatty liver: Exacerbates risk; tigecycline has caused failures in non-alcoholic steatohepatitis (NASH) trials.[5]
- Concurrent hepatotoxins: Drugs like acetaminophen or other antibiotics amplify damage; avoid in polypharmacy cases.[1]
How common is liver damage, and what does monitoring look like?
Hepatotoxicity occurs in 1-10% of patients, mostly asymptomatic transaminase rises resolving post-treatment. Severe cases (jaundice, failure) are rare (<0.1%) but prompted FDA warnings. Baseline and weekly LFTs are standard; discontinue if ALT >5x ULN or symptoms appear.[1][2]
Are there safer alternatives for at-risk adults?
For liver-compromised patients, options include:
- Meropenem or piperacillin-tazobactam (less hepatic metabolism).[3]
- Ceftazidime-avibactam for resistant infections, with renal adjustments instead.[6]
Consult ID specialists; tigecycline's broad-spectrum utility persists in polymicrobial cases without alternatives.[1]
Sources
[1]: Tigecycline Prescribing Information (FDA)
[2]: LiverTox: Tigecycline (NIH)
[3]: Lexicomp: Tigecycline Dosing in Hepatic Impairment
[4]: Obesity and Tigecycline Hepatotoxicity (PubMed)
[5]: Tigecycline in NASH (Hepatology Journal)
[6]: IDSA Guidelines for Resistant Infections